Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Alte Biosciences Licenses Technology for Depression Drugs from Duke

  • Alte Biosciences secured exclusive rights to IP developed at the Duke University Medical Center for drugs targeting late-onset depression and related disorders.

    The licensed technology is a patent based on findings by Ranga Krishnan, M.D., related to the relationship between cerebrovascular disease and the onset of depression in elderly individuals, a disease called vascular depression. Dr. Krishnan is professor and chairman of the department of psychiatry and behavioral sciences at Duke University Medical Center.

    The company will immediately focus on conducting the regulatory studies needed to advance the lead candidate, ARX-111, into a clinical proof-of-concept study within the next 12 months, according to Thomas Colatsky, Ph.D., CSO for Alte Biosciences.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »